Novo Nordisk Raises 2026 Outlook on GLP-1 Demand, Takes DKK 6.3 Bln Impairment
Novo Nordisk lifted its 2026 adjusted sales and operating profit forecast to a range of 0% to -6% at constant exchange rates, driven by increased expectations for GLP-1 product sales. The company also recorded a DKK 6.3 billion non-cash impairment charge in Q2 tied to intangible pipeline assets.
Novo Nordisk increased its 2026 outlook for adjusted sales and operating profit, now projecting a range of 0% to -6% at constant exchange rates. The Danish drugmaker said the improvement reflects rising expectations for its GLP-1 product portfolio, which includes popular diabetes and weight-loss treatments.
The improved forecast was announced alongside a DKK 6.3 billion non-recurring, non-cash impairment charge in the second quarter. The write-down is linked to intangible assets in the company’s pipeline, signaling reduced valuations for certain development projects.
The outlook upgrade highlights continued strong commercial momentum for GLP-1 therapies, even as the company takes a one-time accounting hit on earlier-stage pipeline investments.
Source: First Squawk